MapLight Therapeutics (MPLT) Capital Expenditures (2024 - 2025)

MapLight Therapeutics (MPLT) reported Capital Expenditures of $376000.0 for Q4 2025, up 254.72% on a YoY basis from $106000.0 in Q4 2024, and up 254.72% sequentially from $106000.0 in Q4 2024.

MapLight Therapeutics (MPLT) Capital Expenditures (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Capital Expenditures data on file, last reported at $376000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -8,939.03
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 43.25 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 133.40 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 230.60 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 786,000.00
10 MapLight Therapeutics 314.07 Mn 314.07 Mn - 376,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 376,000.00
Dec 31, 2025 376,000.00
Dec 31, 2024 106,000.00
Dec 31, 2024 106,000.00